Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Sullivan

Showing results (141-150 of 327) with videos related to

Pageof 33
Sort By:
Journal of the American Academy of Dermatology|February 22, 2023
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanomaMichael R Stephens, Maria S Asdourian, Ted V Jacoby, et al.
The Oncologist|June 14, 2025
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancerRyan J Sullivan, Oladapo O Yeku, Deanna Teoh, et al.
Cancer|December 7, 2018
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapyKarim R Saab, Meghan J Mooradian, Daniel Y Wang, et al.
Nature Medicine|August 22, 2018
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanomaNoam Auslander, Gao Zhang, Joo Sang Lee, et al.
JCO Oncology Practice|July 22, 2024
Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative StudyMary C Boulanger, Ayo S Falade, Kelly Hsu, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designsTian Zhang, Patrick M Forde, Ryan J Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
Advances in Radiation Oncology|January 23, 2024
Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent LiteratureAlicia C Smart, Anita Giobbie-Hurder, Vineet Desai, et al.
Neurology|August 14, 2019
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathiesDivyanshu Dubey, William S David, Anthony A Amato, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 2, 2019
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint InhibitorsHarish Seethapathy, Sophia Zhao, Donald F Chute, et al.
Pageof 33

Showing results (141-150 of 327) with videos related to

Sort By:
Pageof 33
Journal of the American Academy of Dermatology|February 22, 2023
Tumor-infiltrating lymphocytes as a predictive biomarker of cutaneous immune-related adverse events after immune checkpoint blockade in patients with advanced melanomaMichael R Stephens, Maria S Asdourian, Ted V Jacoby, et al.
The Oncologist|June 14, 2025
First-in-human phase I/II, open-label study of mRNA-2416 alone or combined with durvalumab in patients with advanced solid tumors and ovarian cancerRyan J Sullivan, Oladapo O Yeku, Deanna Teoh, et al.
Cancer|December 7, 2018
Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapyKarim R Saab, Meghan J Mooradian, Daniel Y Wang, et al.
Nature Medicine|August 22, 2018
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanomaNoam Auslander, Gao Zhang, Joo Sang Lee, et al.
JCO Oncology Practice|July 22, 2024
Patient and Caregiver Experience With the Hope and Prognostic Uncertainty of Immunotherapy: A Qualitative StudyMary C Boulanger, Ayo S Falade, Kelly Hsu, et al.
Journal for Immunotherapy of Cancer|May 3, 2023
Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designsTian Zhang, Patrick M Forde, Ryan J Sullivan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with <i>BRAF</i> -mutant Solid TumorsRyan J Sullivan, Jeffrey Weber, Sapna Patel, et al.
Advances in Radiation Oncology|January 23, 2024
Multicenter Evaluation of Radiation and Immune Checkpoint Inhibitor Therapy in Mucosal Melanoma and Review of Recent LiteratureAlicia C Smart, Anita Giobbie-Hurder, Vineet Desai, et al.
Neurology|August 14, 2019
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathiesDivyanshu Dubey, William S David, Anthony A Amato, et al.
Clinical Journal of the American Society of Nephrology : CJASN|November 2, 2019
The Incidence, Causes, and Risk Factors of Acute Kidney Injury in Patients Receiving Immune Checkpoint InhibitorsHarish Seethapathy, Sophia Zhao, Donald F Chute, et al.
Pageof 33